logo

DYN

Dyne·NASDAQ
--
--(--)
--
--(--)
3.96 / 10
Netural

Dyne Therapeutics' fundamentals score 3.96/10, classified as neutral. Key strengths include positive Profit-MV (0.4743) and Net income-Revenue (-0.1516), while headwinds are evident in Revenue-MV (-0.2641) and Gross profit margin (36.70%), placing the company in lower-performing quartiles for several metrics. Historical back-tests show modest one-month returns (e.g., 7.95% for Profit-MV group 1) but overall constrained upside potential.

Fundamental(3.96)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight9.76%
1M Return5.63%
Inventory turnover ratio
Value47.88
Score3/3
Weight8.94%
1M Return5.89%
Gross profit margin (%)
Value36.70
Score1/3
Weight0.28%
1M Return0.22%
Profit-MV
Value0.47
Score2/3
Weight13.66%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight13.85%
1M Return8.04%
PB-ROE
Value0.60
Score0/3
Weight7.01%
1M Return4.05%
Current assets turnover ratio
Value1.78
Score2/3
Weight2.42%
1M Return1.75%
Fixed assets turnover ratio
Value7993.84
Score3/3
Weight2.06%
1M Return1.53%
Asset-MV
Value-0.51
Score3/3
Weight28.48%
1M Return14.63%
Cash-MV
Value-0.07
Score2/3
Weight13.54%
1M Return7.78%
Is DYN undervalued or overvalued?
  • DYN scores 3.96/10 on fundamentals and holds a Fair valuation at present. Backed by its -50.58% ROE, 0.00% net margin, -6.58 P/E ratio, 3.93 P/B ratio, and -1.12% earnings growth, these metrics solidify its Netural investment rating.